Eurofins Announces the Completion of the Acquisition of Beacon Discovery, Inc.
Release date: 3/1/2021
Eurofins announces the completion of the acquisition of Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research.
March 1, 2021
Dear Eurofins Discovery Customer,
Today, Eurofins announces the completion of the acquisition of Beacon Discovery, Inc., a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research.
Beacon Discovery provides early drug discovery research to global biotech and pharmaceutical companies and the acquisition will complement Eurofins’ market leading portfolio of services. Beacon Discovery has many years of experience providing innovation in GPCR research, with particular expertise in prosecuting orphan GPCR programs complemented by their unique compound library.
The acquisition of Beacon Discovery supports Eurofins’ strategy to be the partner of choice to the pharmaceutical industry providing drug discovery experience, knowledge, and a proven track record in supporting the discovery and development of new therapeutics. The combination of Beacon Discovery with Eurofins’ existing in vitro pharmacology, ADMET, and chemistry services further enables Eurofins’ ability to support fully integrated drug discovery programs from target validation to pre-clinical candidate through its DiscoveryOne™ services.
As a valued customer of Eurofins Discovery, we believe that this expansion of our services through the acquisition of Beacon Discovery will be of interest. If you have any questions about this good news and opportunities this may bring to you, please contact us at any time. We look forward to introducing you to Beacon Discovery and their scientific teams. Please contact your local Eurofins Discovery representative or client services (EurofinsDiscovery@eurofins.com) for further information.
Eurofins would like to thank you for your continued support and partnership, and we hope that bringing Beacon Discovery’s expertise and capabilities into Eurofins Discovery will lead to further areas of collaboration between our organizations.
Christina Shasserre, SVP Eurofins Discovery
Founded in 2016 and headquartered in San Diego, Beacon Discovery is a world leader in GPCR-focused drug discovery. Beacon’s mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic. Beacon’s internal pipeline focuses on GPCRs for which the native ligand remains unknown. These orphan GPCRs provide unexploited opportunities to develop novel drugs addressing significant unmet medical need. In addition, Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small molecule modulators as well as its wealth of GPCR discovery skills and tools.
About Eurofins Discovery
Eurofins Discovery has been supporting Drug Discovery research for >40 years. Through the combined expertise of Cerep, DiscoverX, EMD Millipore Drug Discovery Solutions, Panlabs, Selcia Drug Discovery, and Villapharma Eurofins Discovery offers the broadest portfolio of drug discovery products and services in the industry. Offerings include medicinal and synthetic chemistry, in vitro pharmacology, safety pharmacology, ADME-Tox, cell-based phenotypic assays, in vivo* safety & efficacy, and custom proteins and assay development. Eurofins Discovery clients have the choice to direct these activities, or utilize Eurofins Discovery’s DiscoveryOne™ program managed services. Eurofins Discovery’s combined capabilities, expertise, knowledge, and skill sets enable providing their clients with the additional benefit of being able to work with a single outsourcing provider (CRO).
*provided by our Partner Lab Pharmacology Discovery Services